Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of the Effect of Ascending Single Doses of DG3173 and 300 μg of Octreotide on Human Growth Hormone Levels in Untreated Acromegalics.

NCT02235987 is registered in ClinicalTrials.gov with Aspireo Pharmaceuticals Limited as lead sponsor.

NCT NCT02235987
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02235987 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of the Effect of Ascending Single Doses of DG3173 and 300 μg of Octreotide on Human Growth Hormone Levels in Untreated Acromegalics.
Lead sponsor
Aspireo Pharmaceuticals Limited
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2012
Completion date
April 30, 2014
Enrollment
20 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acromegaly